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Summary 
 
We have shown that a number of anticonvulsant drugs can reduce glutamate release at 
synapses in the rat entorhinal cortex (EC) in vitro. We have also shown that presynaptic 
NMDA receptors (NMDAr) tonically facilitate glutamate release at these synapses. In the 
present study we determined whether, phenytoin, gabapentin and felbamate may reduce 
glutamate release by blocking the presynaptic NMDAr. Whole cell patch clamp 
recordings of spontaneous excitatory postsynaptic currents (sEPSCs) were used as a 
monitor of presynaptic glutamate release. Postsynaptic NMDAr were blocked with 
internal dialysis with an NMDAr channel blocker. The antagonist, 2-AP5, reduced the 
frequency of sEPSCs by blocking the presynaptic facilitatory NMDAr, but did not 
occlude a reduction in sEPSC frequency by gabapentin or phenytoin. Felbamate also 
reduced sEPSC frequency, but this effect was occluded by prior application of 2-AP5. 
Thus, whilst all three drugs can reduce glutamate release, only the action of felbamate 
seems to be due to interaction with presynaptic NMDAr. 
 
 
Key words: entorhinal cortex, presynaptic NMDA receptors, glutamate release, 
phenytoin, felbamate, gabapentin. 
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1. Introduction 
 
Experiments in this laboratory have shown that the anticonvulsant drugs phenytoin, 
lamotrigine, gabapentin, pregabalin and valproate can reduce the spontaneous release of 
glutamate from excitatory terminals in the rat entorhinal cortex (EC) in vitro 
(Cunningham and Jones, 2000; Cunningham et al., 2000; 2003; 2004). The effect of 
valproate alone appeared to depend on blockade of voltage-gated sodium channels 
(VGSC; Cunningham et al., 2003), whereas the reduction in release elicited by the others 
drugs was independent of any action on sodium channels. Gabapentin and pregabalin 
appeared to act partly via an action on voltage-gated calcium channels (VGCC), and 
partly via an unknown mechanism (Cunningham et al., 2004). 
 
We have also previously shown that glutamate release in the EC is tonically facilitated by 
ambient glutamate acting via presynaptic NMDA autoreceptors (Berretta and Jones, 
1996a; Woodhall et al., 2001; Yang et al., 2006), an effect confirmed in visual cortex (Li 
and Han, 2007). Recently, it has been suggested that gabapentin may interact with 
presynaptic NMDA receptors (NMDAr) in the hippocampus (Suarez et al., 2005). 
Furthermore, pregabilin has been suggested to reduce GABA and, possibly, glutamate 
release in hippocampal cultures via an interaction with presynaptic NMDAr (Micheva et 
al., 2006). There is some evidence, albeit scant, to suggest that phenytoin may block 
NMDAr (e.g. Wamil and McClean, 1993; Naskar et al., 2002), and that it may reduce 
NMDAr-stimulated monoamine transmitter release (Sethy and Sage, 1992; Brown et al., 
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1994). Thus, we have considered the possibility that the reduction of glutamate release by 
anticonvulsants in the EC may depend on blockade of presynaptic facilitatory NMDAr.  
 
To investigate this possibility we monitored glutamate release in rat EC slices by 
recording spontaneous excitatory postsynaptic currents (sEPSCs) mediated by AMPA 
receptors (AMPAr) using whole-cell voltage clamp recordings. When postsynaptic 
NMDAr are blocked by inclusion of MK801 in the patch pipette, competitive NMDAr 
antagonists reduce the frequency (but not amplitude or kinetics) of sEPSCs, by blocking 
the tonic presynaptic facilitation of release (Berretta and Jones, 1996a; Woodhall et al., 
2001; Yang et al., 2006; Li and Han, 2007). Thus, we determined whether the reduction 
in frequency of sEPSCs by phenytoin and gabapentin (Cunningham et al., 2000; 2004) 
could be occluded by prior blockade of presynaptic NMDAr. We compared the effects of 
these two drugs to those of felbamate, a second-generation anticonvulsant. Felbamate has 
consistently been shown to block NMDAr-mediated currents (e.g. Harty and Rogawski, 
2000; Kuo et al., 2004), so could also potentially alter glutamate release via an action at 
presynaptic NMDAr. 
 
The results suggest that the VGSC-independent reduction of glutamate release by 
phenytoin is not due to blockade of presynaptic NMDAr, nor is the VGCC-independent 
effect of gabapentin. However, felbamate does appear to reduce release via presynaptic 
NMDAr blockade, and this could be a factor in its anticonvulsant effect.  
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2. Methods 
 
Combined entorhinal-hippocampal slices were prepared from male Wistar rats, as 
previously described (Jones and Heinemann, 1988). Rats were killed by cervical 
dislocation. They were decapitated and the brain was rapidly removed and immersed in 
oxygenated artificial cerebrospinal fluid (ACSF) chilled to 4°C. Slices (450 µm) were cut 
using a Vibroslice, and stored in ACSF bubbled with 95% O2/5% CO2, at room 
temperature. Following recovery for at least 1 hour, individual slices were transferred to a 
recording chamber mounted on the stage of a Zeiss Axioskop FS microscope. The 
chamber was perfused (2 ml/min) with oxygenated ACSF (pH 7.4) at 30-32 °C. The 
ACSF contained (in mM): NaCl (126), KCl (3.25), NaH2PO4 (1.25), NaHCO3 (24), 
MgSO4 (2), CaCl2 (2.5), and d-glucose (10). Neurones were visualized using differential 
interference contrast optics and an infrared video camera.  
 
Patch pipettes (1-4 MΩ) were pulled from borosilicate glass on a Flaming/Brown 
microelectrode puller. Pipettes were filled with a solution containing (in mM): Cs-
Gluconate (100), HEPES (40), QX-314 (1), EGTA (0.6), NaCl (4), MgCl2 (5), TEA-Cl 
(1), ATP-Na (4), GTP-Na (0.3), MK-801 (1). The solution was adjusted to 275 mOsmol 
by dilution, and set to pH 7.3 with CsOH. Whole cell voltage clamp recordings were 
made from neurones in layer V of the medial division of the EC, using an Axopatch 200B 
amplifier. Using this pipette solution and with membrane potential clamped at -60 mV, 
neurones displayed sEPSCs. The open channel blocker, MK-801, was included in the 
patch pipette in order to block postsynaptic NMDAr in the recorded neurone. To facilitate 
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this blockade, neurones were depolarised to –10 mV for 10 s at intervals (every 20 s) 
during a 10 minute period following breakthrough to whole-cell access. Using this 
approach NMDAr mediated EPSCs are rapidly abolished.  
 
The use of intracellular MK-801 to block postsynaptic responses has been described in 
detail by us previously (Berretta and Jones, 1996a; Woodhall et al., 2001; Yang et al., 
2006). Fig.1 shows an experiment that confirms the ability of MK-801 to block 
postsynaptic NMDAr. In this case, EPSCs were evoked (eEPSC) by electrical stimulation 
in layer V of the lateral EC, with MK-801 in the patch pipette, and at a holding potential 
of -60 mV (Fig. 1A). Blockade of AMPA and GABA receptors left a small shallow 
eEPSC. When the holding potential was changed to +40 mV (Fig. 1B), this was revealed 
as a large slow NMDAr mediated eEPSC. The holding potential was then stepped 
repetitively from -60 to -10 mV (for just 5 minutes in this case), and subsequent 
stimulation at +40 mV showed that the eEPSC was now abolished. This approach has 
become a widely accepted means of selectively blocking postsynaptic NMDAr, leaving 
presynaptic receptors intact, and has been used successfully by a number of other groups 
in cortical hippocampal and amygdala neurones (e.g. Sjostrom et al., 2003; Massey et al., 
2004; Samson and Pare, 2005; Bender et al., 2006; Jourdain et al., 2007; Li and Han, 
2007).  
 
Even when postsynaptic receptors are not blocked with MK-801, spontaneous events 
mediated solely by NMDAr are very infrequent, and there is only a minor contribution of 
NMDAr to the decay phase of sEPSCs (Berretta and Jones, 1996b). In these 
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circumstances, sEPSCs are abolished by bath application of NBQX and 2-AP5 (e.g. 
Stacey et al., 2002). Fig. 1C shows recordings of sEPSCs in one neurone and confirms 
that with postsynaptic NMDAr blocked with intracellular MK-801, addition of an 
AMPAr antagonist abolishes all spontaneous currents. It should be stressed that all the 
recordings presented in this paper were conducted with postsynaptic NMDAr blocked 
and under these experimental conditions, sEPSCs are mediated by glutamate acting at 
AMPA receptors (Berretta and Jones, 1996b; Woodhall et al., 2001). In other 
experiments in this laboratory (Chamberlain, S.E.L. and Jones, R.S.G.) we have shown 
that kainate receptors can mediate postsynaptic excitatory responses in the EC, but these 
receptors are not activated by spontaneously released glutamate. Thus, sEPSCs in our 
recordings are mediated solely by AMPAr. 
 
The experimental protocols required patch clamp recordings for periods of up to 60 
minutes, so we had to consider the possibility that changes in sEPSCs might be 
complicated by run-down of events. However, the inclusion of ATP-Na and GTP-Na 
largely precluded this, and we have previously made similar long duration patch clamp 
recordings of sEPSCs in many studies without any problems regarding stability (e.g. 
Berretta and Jones, 1996a,b; Cunningham et al., 2000; 2003; 2004; Cunningham and 
Jones, 2001; Evans et al., 2001; Woodhall et al., 2001; Stacey et al., 2002; Yang et al., 
2006). Series resistance compensation was not employed in the present experiments, but 
access resistance (10-30 MΩ) was monitored at regular intervals throughout and neurones 
were discarded from analysis if it changed by more than ±10%. Liquid junction potentials 
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were estimated using the calculator of pClamp 8 software, and compensated for in the 
holding potentials. 
 
After gaining whole cell access, and allowing time for MK-801 to diffuse into the 
neurone and block the postsynaptic NMDAr (with repeated depolarizations), the neurone 
was then allowed to stabilize for a further control period of not less than 10 minutes after 
which sEPSCs were recorded. 2-AP5 was then added to the perfusion medium for a 
period of 20 min before further addition of an anticonvulsant and perfusion of both drugs 
for a further 20 min. In a second series of experiments, the drugs were perfused in reverse 
order. sEPSCs were recorded throughout and analysis periods confined to the final 5 
minutes of perfusion with one, and then both drugs.  
 
Data were recorded to computer hard disk using Axoscope software. Minianalysis 
(Synaptosoft, U.S.A.) was used for analysis of sEPSCs off-line. sEPSCs were detected 
automatically using a threshold-crossing algorithm. Threshold varied from neurone to 
neurone, but was always maintained at a constant level in each individual recording. 200 
sEPSCs were sampled during a continuous recording period for each neurone under each 
condition. The populations of events sampled were mixed, and represent both activity-
dependent and activity-independent miniature EPSCs (mEPSCs) from multiple terminals 
on the same neurones, although the majority of events (around 60-70%) are mEPSCs (see 
Berretta and Jones, 1996b). No attempt was made to separate these in the present study, 
but we have previously shown that both presynaptic NMDAr can facilitate both forms of 
release (Berretta and Jones, 1996; Woodhall et al., 2001) and also that phenytoin and 
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gabapentin depress the frequency of both sEPSCs, and mEPSCs recorded in the presence 
of TTX (Cunningham et al., 2000; 2004).  To compare pooled data under control and 
drug conditions we determined mean inter-event interval (IEI), the frequency derived 
from the IEI, amplitude, and rise and decay times for sEPSCs in each cell. A paired t-test 
was used to compare mean amplitudes and frequencies, rise and decay times, and the 
non-parametric Kolmogorov-Smirnoff (KS) test to assess the significance of shifts in 
cumulative probability distributions of IEI. All error values stated in the text refer to 
standard error of the mean. 
  
The following drugs were used: 2-AP5 (D,L-2-amino-5-phosphonovalerate; Tocris, UK); 
phenytoin sodium (Sigma, UK); gabapentin (1-(aminomethyl)cycloheaneacetic acid; a 
gift from Pfizer, Global Research & Development, Ann Arbor, Michigan); felbamate (2-
phenyl-1,3-propanediol dicarbamate; Tocris, UK). 
 
3. Results 
 
Experiments were performed on a total of 21 neurones in layer V of the medial EC. 
sEPSCs in control recordings had a mean IEI of 291±44 ms (equating to a frequency of 
5.3±0.7 Hz), an amplitude of 12.0±0.9 pA, and rise (10-90%) and decay times (60%) of 
1.9±0.1 ms and 5.8±0.9 ms, respectively. 
 
 
 
Deleted: and 
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3.1 Phenytoin. 
 
In 3 neurones, perfusion with 2-AP5 (50 µM) increased the mean IEI of sEPSCs from 
211±66 ms to 327±117 ms (reflecting a decrease in frequency from 6.5±2.9 Hz to 
4.2±1.7 Hz, P<0.01), with no significant change in amplitude (10.2±1.0 v 12.2±1.7 pA). 
The decrease in frequency without change in amplitude or kinetics (see below) is strongly 
indicative of a presynaptic effect, and, as we have previously demonstrated, reflects 
blockade of the tonic facilitation of glutamate release via the presynaptic NMDA 
autoreceptor (Berretta and Jones, 1996a; Woodhall et al., 2001). In the same neurones, 
subsequent addition of phenytoin (50 µM in the presence of 2-AP5) caused a further 
increase in IEI to 459±175 ms (3.4±1.6Hz, P<0.05), again without change in amplitude. 
Fig. 2A shows examples of voltage clamp recordings from one neurone, and cumulative 
probability analysis of IEI in pooled data from all three neurones, showing the shift 
towards longer intervals in the presence of 2-AP5 and a further shift to the left with the 
addition of phenytoin, are illustrated in Fig. 2B. On average, the frequency of sEPSCs 
was reduced by -37±8% by 2-AP5. With the addition of the anticonvulsant the total 
reduction compared to control was -55±3%. Comparing the frequency of events in 
phenytoin plus 2-AP5 to 2-AP5 alone gave an average reduction of -21±4%. sEPSC rise 
times (10-90%) were 2.0±0.4 ms in control, 2.1±0.2 ms in the presence of 2-AP5, and 
2.6±0.6 ms with subsequent addition of phenytoin. Corresponding times to 60% decay 
were 5.1±2.0 ms, 5.6±2.3 ms and 5.4±1.4 ms, respectively. 
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We conducted the reverse experiment in a further 4 neurones. Phenytoin applied alone 
increased IEI from 163±36 ms to 250±43 ms, and subsequent perfusion with 2-AP5 
resulted in a further increase in IEI to 630±258 ms. The respective changes in sEPSC 
frequency were from 7.8±2.5 Hz to 4.6±1.1 (P=0.05) with phenytoin, and to 2.4±0.8% 
(P<0.01) on addition of 2-AP5. Again, there were no changes in amplitude (not shown). 
The pooled cumulative probability analysis for IEI data are illustrated in Fig. 2C, 
showing clearly the shift towards longer intervals in phenytoin, and a further shift when 
2-AP5 was added. The mean reductions in sEPSC frequency were -37±4% with 
phenytoin alone, and -71±7 % when both drugs were present. This corresponds to a 
decrease in frequency of -47±10% when comparing phenytoin alone to phenytoin plus 2-
AP5. 
 
Rise (control 1.5±0.1 ms; phenytoin 2.1± 0.5 ms; phenytoin plus 2-AP5 1.8±0.4 ms) and 
decay times (5.3±0.3 ms v 5.4±0.2 ms v 5.3±0.3 ms) were again unaltered   
 
3.2. Felbamate 
 
In three neurones 2-AP5 (50 µM) again reduced glutamate release, reflected by an 
increase in mean IEI (from 522±154 ms to 950±325 ms; frequency 2.1±0.6 to 1.2±0.3 
Hz, P<0.05) with no obvious change in sEPSC amplitude (13.5±3.1 v 12.5±1 pA). 
However, subsequent addition of felbamate (100 µM), elicited no further change in IEI 
(883±277 ms). In fact, in two neurones, sEPSC frequency was slightly increased when 
felbamate was added, although overall there was no marked change (1.3±0.3Hz, P>0.1), 
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and again amplitude remained about the same (12.6±1.2 Hz). Fig. 3A shows voltage 
clamp recordings from one neurone and the cumulative probability analysis of pooled 
data are illustrated in Fig. 3B. sEPSC rise times were unaltered at 2.0±0.4 ms in control, 
2.4±0.3 ms in the presence of 2-AP5, and 2.5±0.4 ms with the addition of felbamate. 
Corresponding times to 60% decay were 5.3±1.8 ms, 6.0±1.2 ms and 5.8±1.9 ms, 
respectively. 
 
The reverse experiment was conducted in 4 neurones and gave very similar results. 
Felbamate alone decreased EPSC frequency from 5.1±1.1 Hz to 2.5±0.9 Hz (P<0.01), IEI 
increasing from 238±67 v 587±193 ms. Now, addition of 2-AP5 failed to cause any 
significant further change (2.6±0.9 Hz; 528±140 ms). The pooled cumulative probability 
data for IEI from the 4 neurones can be seen in Fig. 3C.Mean amplitudes were essentially 
the same throughout (11.2±3.8 v 10.7±4.1 v 11.2±4.5 pA). Rise times were also unaltered 
(control 2.2±0.6 ms; felbamate 2.2± 0.7 ms; felbamate plus 2-AP5 2.4±0.6 ms), as were 
decay times (4.8±0.6 ms v 4.7±0.7 ms v 4.4±0.5 ms.  
 
The normalised data supported the observation that the NMDA antagonist and the 
anticonvulsant could occlude each other’s effects. Thus, application of 2-AP5 reduced 
sEPSC frequency by -48±3%, and the percentage reduction in the presence of both 2-AP5 
and felbamate was virtually the same at -43±1%. When the effect of felbamate was 
normalised to the frequency in 2-AP5, there was a slight increase to +10±5%. 
Application of felbamate alone in the second set of experiments reduced frequency by -
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55±9% and with addition of 2-AP5 the total reduction was -52±8%. This reflected a 
change of +7±12% when 2-AP5 was normalised to the frequency in felbamate alone.  
 
3.3. Gabapentin 
 
Gabapentin has been suggested to target presynaptic NMDAr (Suarez et al., 2005), so we 
compared its effects to those of the other anticonvulsants. sEPSC frequency in 3 neurones 
was significantly (P<0.05) reduced from 6.8±2 to 3.1±1.4 Hz (IEI: 188±72 v 552±290 
ms) during perfusion with 2-AP5. Addition of gabapentin (25 µM) caused a further 
reduction (P<0.05) to 1.6±0.4 Hz (693±191 ms). Amplitudes were not significantly 
altered throughout (11.5±2.5 v 12.2±4.2 v 11.8±4.2 pA), as were rise times (1.6±0.4 v 
2.1±0.8 v 1.9±0.3 ms) and decay times (5.7±0.6 v 6.0±0.8 v 5.6±0.5 ms). One study is 
illustrated in Fig. 4A, with pooled data from the three neurones summarized in Fig. 4B. 
Similar results were obtained when gabapentin was applied prior to 2-AP5 (n=4). In this 
case IEI was increased from 304±85 ms to 712±146 ms by the anticonvulsant (KS 
P<0.01) with a further increase to 1049±397 ms when 2-AP5 was added (KS P<0.01). 
The results of the pooled IEI analysis are shown in Fig. 4C. As in previous studies, rise 
times, decay times and amplitudes were unaltered throughout (not shown).  
 
The normalised data also indicated a lack of occlusion between the two drugs. Thus, 2-
AP5 reduced sEPSC frequency by -45±11% when applied alone and the total reduction 
with subsequent addition of gabapentin was -60±17%. Comparing 2-AP5 alone to 2-AP5 
plus gabapentin gave an average reduction of -30±18%. In the reverse experiments, 
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gabapentin reduced sEPSC frequency by -58±5% and together with 2-AP5 the reduction 
was -68±4%. Normalizing the 2-AP5 data to the frequency in the presence of gabapentin 
gave a reduction of -21±13%. 
 
4. Discussion. 
 
The anticonvulsant effect of phenytoin has traditionally been associated with its ability to 
exert a use- and frequency-dependent block of VGSC, thereby reducing sustained 
repetitive firing of action potentials in cortical neurones (see Rogawski and Loscher, 
2004). However, we have shown previously that phenytoin reduces the frequency but not 
amplitude of sEPSCs in the EC, suggesting that it also acts presynaptically to reduce 
glutamate release. Moreover, this effect persists in the presence of tetrodotoxin, which 
suggests that it occurs independently of VGSC-blockade and we have suggested that it 
occurs downstream of Ca-entry into glutamate terminals (Cunningham et al., 2000). We 
have also shown that glutamate release is tonically facilitated by Ca-entry through 
presynaptic NMDAr in the EC (Woodhall et al., 2001), so we considered the possibility 
that reduction of glutamate release could occur via blockade of this receptor. The current 
experiments suggest that this is unlikely to be the case. The reduction in sEPSC 
frequency induced by phenytoin was not occluded by prior blockade of presynaptic 
NMDAr with 2-AP5 (nor vice versa). This argues strongly against a role of blockade of 
the facilitatory autoreceptor in the action of phenytoin at glutamate terminals.  
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Thus, the VGSC-independent mechanism of phenytoin on glutamate release therefore 
remains unknown. One possibility is that phenytoin interferes with the release mechanism 
via inhibition of PKC (see Cunningham et al., 2000). Another possibility is that it 
disrupts release via a direct action on the vesicles. For example, the novel anticonvulsant, 
levetiractem, binds specifically to the vesicle associated protein, SV2A (Lynch et al., 
2004). It is conceivable that phenytoin may also act directly on the release process by 
altering the exocytotic process. 
 
The present study shows that felbamate, like the other drugs we have tested previously 
(Cunningham et al., 2000; 2003; 2004; Cunningham and Jones, 2000), reduces the 
frequency, but not amplitude of sEPSCs in EC neurones, suggesting a target on or in 
presynaptic glutamate terminals. Unlike phenytoin, however, this effect was completely 
occluded by pre-perfusion with 2-AP5, and the reverse experiment produced the same 
result. This clearly indicates that felbamate can act to block presynaptic NMDAr and 
thereby reduce the tonic positive feedback facilitation of glutamate release. This effect 
may not be completely surprising in view of the fact that felbamate has repeatedly been 
shown to act as an NMDAr blocker (Rho et al., 1984; Subramaniam et al., 1995; Kuo et 
al., 2004), as a result of either an interaction with the glycine site of the receptor (e.g. 
White et al., 1995; Kuo et al., 2004) or as a result of open channel blockade 
(Subramaniam et al., 1995; Harty and Rogawski, 2000). Whatever its action, it is 
significant that it has shown to be more selective for NR1-NR2B heteromeric channels 
(Kleckner et al., 1999; Harty and Rogawski, 2000). This would agree with our previous 
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studies, which have shown that the presynaptic NMDAr is likely to be primarily NR2B 
(Woodhall et al., 2001; Yang et al., 2006).  
 
Felbamate has also been shown to block VGCC (Stefani et al., 1996). This is unlikely to 
be involved in the reduction of glutamate release that we see, as it appears to be specific 
for L-type channels, and glutamate release at EC synapses is likely to be mediated by a 
combination of N, P/Q and R type channels (Cunningham et al., 2004; Woodhall et al., 
2007). In addition, felbamate may also block VGSC (Taglialatela et al., 1996) leading to 
a reduction in sustained repetitive firing (White et al., 1992; Pisani et al., 1995), and has 
also been suggested to enhance GABAAr mediated currents (Rho et al., 1997; Kume et 
al., 1996). Any, or all, of these effects could be involved in the anticonvulsant actions of 
felbamate, but our results suggest that a reduction of the positive feedback control of 
glutamate release via presynaptic NMDAr needs to be included in this panoply of actions. 
 
Suarez et al. (2005) recently suggested that presynaptic NMDAr on Schaffer-
commissural fibres increase axonal excitability in CA1 as a result of increased Na-entry 
via the receptor. This differs from the situation in the EC where the facilitatory effect of 
presynaptic NMDAr on glutamate release is dependent on Ca-entry via the receptor 
ionophore (Woodhall et al., 2001). The present data also suggest that the ability of 
gabapentin to block the presynaptic NMDAr in the hippocampus is not reflected by a 
similar action in the EC. Thus, the reduction in glutamate release we previously reported 
with gabapentin (Cunningham et al., 2004) was not occluded by prior blockade of the 
receptor with 2-AP5 (nor vice versa). Our previous data (Cunningham et al., 2004) 
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suggest that gabapentin may reduce glutamate release partly by blockade of Ca-entry via 
VGCC and partly by an unknown mechanism. The current experiments suggest that the 
latter is unlikely to be linked to blockade of presynaptic NMDAr. Whilst we cannot 
completely rule out an action of gabapentin at the facilitatory autoreceptor, it seems 
unlikely that this plays a major role in its anticonvulsant action. 
 
In conclusion, we have shown that felbamate, like phenytoin, lamotrigine, gabapentin, 
pregabilin and valproate (Cunningham and Jones, 2000; Cunningham et al., 2000; 2003; 
2004), reduces the release of glutamate at excitatory synapses in the EC. However, in 
contrast to at least two of these drugs, the action of felbamate seems to be largely due to 
blockade of presynaptic facilitatory NMDA autoreceptors. Thus, whilst a reduction in 
synaptic excitation may be a common underlying mechanism involved in anticonvulsant 
actions, different drugs may achieve this by very different means. We have recently 
shown that there is a developmental decline in the facilitation of glutamate release by 
presynapticNMDAr in the EC, but this effect is reversed in the cortex of chronically 
epileptic animals (Yang et al., 2006). Thus, enhanced NMDAr mediated glutamate 
release could well contribute to epileptogenesis, and the ability of felbamate to block this 
might be a very important aspect of its anticonvulsant actions. Although the present data 
suggest that other drugs such as phenytoin and gabapentin do not appear to exert such an 
action in normal cortex, it is possible that they could do this could change in the 
pathological  condition. Future experiments will address this issue. 
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Figure Legends 
 
Figure 1. Intracellular MK-801 blocks postsynaptic NMDAr. A. The traces are voltage 
clamp recordings of eEPSCs in a layer V neurone (at least 8 responses averaged) evoked 
by electrical stimulation of afferent pathways at 0.33Hz. The large eEPSC seen at a 
holding potential of -60 mV, is replaced by a weak slow eEPSC during perfusion with 
NBQX (10 µM) and bicuculline (30 µM). B. Shifting the holding potential to +40 mV 
revealed a large slow eEPSC that was subsequently abolished by a period of repetitive 
depolarizing steps from -60 mV to -10 mV over a period of 5 minutes. C. Whole cell 
voltage clamp records of sEPSCs in a different layer V neurone. The three traces are 
continuous. The patch pipette contained MK-801, and prior to the recordings illustrated, 
the neurone had been subject to a series of depolarizing voltage steps (as described above 
and in the text) for a period of 10 minutes. Addition of NBQX to the perfusion medium 
(during red bar) rapidly abolished all sEPSCs. 
 
Figure 2. Phenytoin does not act via presynaptic NMDAr. A. Voltage clamp recordings 
from a single layer V neurone. The downward defections are spontaneous sEPSCs 
mediated via glutamate acting at postsynaptic AMPAr. Application of 2-AP5 (50 µM) 
reduced the frequency of sEPSCs, but did not occlude the effect of the subsequent 
addition of phenytoin (50 µM), which caused a substantial further reduction. B. Pooled 
data from 3 neurones (200 events, from each neurone in each condition). The cumulative 
probability curve in the presence of 2-AP5 is significantly (P<0.01) shifted to the left 
towards longer intervals (lower frequency). The addition of phenytoin caused a further 
significant shift (KS, P<0.001). C. In the reverse experiment, phenytoin significantly 
increased IEI (KS, P<0.001), and 2-AP5 caused a further significant shift to the left (KS, 
P<0.001). Pooled data from 4 neurones. 
 
Figure 3. Felbamate acts via the presynaptic NMDAr. Details as in Fig. 1. A. 2-AP5 
(50µM) reduces sEPSC frequency but the addition of felbamate (100µM) has no further 
effect. B. This is confirmed by pooled data for IEI in three neurones where there was a 
significant (KS, P<0.001) leftward shift in the cumulative probability curve in 2-AP5, but 
the distribution with the addition of felbamate is completely overlapping. C. Similar data 
were obtained in the reverse experiment in 4 neurones where felbamate occluded 2-AP5. 
 
Figure 4. Gabapentin does not act via presynaptic NMDAr. Details as in Fig. 1. The 
effect of gabapentin (25 µM) was very similar to that seen with phenytoin (Fig. 1) and 
differed from the occlusion seen with felbamate (Fig. 2).  
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